BACKGROUND: In recent years, there have been a number of pharmacological innovations for Crohn's disease (CD), a difficult-to-treat condition, including new treatment philosophies (e.g., top-down therapy) and new therapeutic options in terms of the agent and the route of administration. Three anti-tumor necrosis factor (anti-TNF-alpha) agents are available for use among CD patients in the United States: infliximab, an intravenous agent, and adalimumab and certolizumab pegol, 2 newer subcutaneous products. Infliximab is considered the "gold standard" because it has the longest clinical experience, and adalimumab and certolizumab pegol have each gained significant market share.
C
rohn's disease (CD), a condition involving chronic inflammation of the gastrointestinal tract, affects more than half a million Americans. 1 CD has an estimated prevalence rate of 241 per 100,000 adults and, as a condition with no cure and low mortality, the number of Americans with CD is increasing. 1 Overall, direct costs associated with CD have reached $3.6 billion annually in the United States, with indirect costs, such as missed work, adding to the economic burden. 2 The exact cause of CD is unknown, but treatments are available to help control symptoms and induce periods of remission.
Step-therapy typically begins with aminosalicylates to control inflammation, progressing to corticosteroids or immunomodulators. 3 If symptoms remain uncontrolled, biological therapies, such as anti-tumor necrosis factor (anti-TNF-alpha) agents, are indicated. 3 The anti-TNF-alpha agents infliximab, adalimumab, and certolizumab pegol are approved by the U.S. Food
• The number of Americans with Crohn's disease (CD), a condition with no cure, is increasing. In the United States, direct costs associated with CD have reached $3.6 billion annually.
• Three anti-tumor necrosis factor (anti-TNF-alpha) agents (infliximab, adalimumab, and certolizumab pegol) were approved by the FDA for the treatment of CD in 1998, 2007, and 2008, respectively. In clinical trials, efficacy rates are similar among the agents, with 60% to 70% of patients showing a response, and all 3 agents are well tolerated.
• Infliximab is administered intravenously (IV), requiring visits to a physician's office or infusion center; adalimumab and certolizumab are subcutaneous (SQ) injections, which allow patients to self-administer treatment.
What is already known about this subject
• This is the first study to compare routes of administration for anti-TNF-alpha agents in a real-world setting, particularly in terms of specific CD-related symptoms and adverse events.
• In this study, the IV and SQ anti-TNF-alpha agents demonstrated similar effectiveness and safety outcomes among patients with CD.
• Given comparable effectiveness and safety outcomes between IV and SQ anti-TNF-alpha agents, other factors, such as patient preference, should be considered when choosing CD therapy. Researchers only had access to a limited dataset; strict measures were taken to preserve anonymity and confidentiality and to ensure full compliance with the 1996 Health Insurance Portability and Accountability Act. This research was exempt from institutional review board approval because it involved a limited study database with masked patient identifiers.
What this study adds

Patient Selection
Patients were required to have at least 1 claim for infliximab, adalimumab, or certolizumab pegol from March 1, 2007, through July 31, 2011 . The date of the first such claim was designated as the index date. Patients were divided into 2 mutually exclusive cohorts based on the initial treatment prescribed: the IV group for anti-TNF-alpha-naïve patients who started on an intravenous anti-TNF-alpha (infliximab), and the SQ group for TNF-naïve patients who started on a subcutaneous anti-TNF-alpha agent (adalimumab or certolizumab pegol).
All patients also had at least 1 claim with a CD diagnosis (International Classification of Diseases, Ninth Revision, Clinical Modification [ICD-9-CM] code 555.X) within 6 months before index date. All patients were required to have continuous medical and pharmacy health plan eligibility for at least 6 months prior to the index date, as well as a minimum of 1 month of follow-up (see Figure 1) . The 6 months of pre-index eligibility was required to assess patients' baseline comorbidities and other health risks, as well as utilization patterns prior to initiating the anti-TNF alpha agents. A relatively short minimum eligibility post-index was established in order to prevent bias in case members of 1 cohort were more likely to leave the and Drug Administration (FDA) for the treatment of moderateto-severe CD when other treatments have failed. Infliximab is administered as an intravenous (IV) infusion; adalimumab and certolizumab pegol are administered subcutaneously (SQ). [4] [5] [6] Whereas most patients must visit a physician's office or infusion center for their doses of infliximab, adalimumab and certolizumab may be administered by patients in their own homes, offering convenience and flexibility. 7 Infliximab has been considered the "gold-standard" anti-TNF-alpha therapy for CD primarily because it was first on the market, and there is a substantial body of research and experience available for the agent. In addition, the newer anti-TNF-alpha agents are becoming increasingly popular as treatment options.
Anti-TNF-alpha agents have demonstrated efficacy in inducing and maintaining remission in people with CD. [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] In its 2011 position statement based on a systematic literature review, the World Congress of Gastroenterology (WCOG) stated that clinical trials of anti-TNF-alpha agents for CD found generally similar response rates for infliximab (65% for 5 milligrams per kilograms [mg/kg] and 70% for 10 mg/kg); adalimumab (60%); and certolizumab (64%), despite using different study populations. [18] [19] [20] [21] The reported potential adverse events include infection-most notably tuberculosis, sepsis, and candidiasis-with reports of malignancies and hepatic toxicities. 16, [22] [23] [24] [25] [26] In a study of certolizumab, with a 26-week follow-up, malignancies were reported in 4 patients-2 each in the 331 patients in the certolizumab group and in the 328 patients in the placebo group. 16 A systematic review of all infliximab trials concluded that 0.5% of patients treated with infliximab developed malignancies compared with 0.06% in the placebo group. Since its approval in 1998, infliximab has accumulated millions of patient-years of data; however, the median followup of clinical studies is 1 year, which may be insufficient time for malignancies to develop. 23 Drug-induced hepatic toxicities are rare in clinical studies, but because of cases reported during postmarketing surveillance, the FDA has issued warnings about the potential for serious liver injury related to use of any of the biologic agents. [4] [5] [6] 26 In clinical trials, the anti-TNF-alpha agents have individually demonstrated efficacy regardless of the route of administration. However, the clinical trials of anti-TNF-alpha agents, while numerous, have been limited to comparisons with placebo; no trials have directly compared established treatment (infliximab, IV group) and newer agents (certolizumab pegol and/or adalimumab, SQ group). Therefore, this study was designed to compare the effectiveness and safety outcomes of IV (infliximab) and SQ (certolizumab pegol and adalimumab) anti-TNF-alpha agents.
insurance plan than the other (e.g., patients leaving the workforce and going on disability due to a worsening condition). Only patients aged 18 years or older were included in the analysis. Patients were excluded if they had any claim for anti-TNF-alpha agents during the 6 months before the index date.
Outcome Measures
The primary outcomes involved the rates of effectiveness. Effectiveness was measured by the incidence of CD-specific complications and symptoms (i.e., anal fissures, abscess, fistula, gastrointestinal hemorrhage, and a combined measure of obstruction, occlusion, stenosis, or intestinal stricture). The secondary outcomes involved rates of safety events. Safety outcomes included the incidence of infections (e.g., candidiasis, sepsis, tuberculosis); cancers (e.g., solid tumor, lymphoma, hematologic malignancies); and hepatic-related conditions. Effectiveness outcomes as well as infection outcomes, except for anaphylaxis, were identified by requiring at least 1 claim containing corresponding ICD-9-CM diagnosis codes following therapy initiation. Anaphylaxis was identified by requiring at least 1 claim with corresponding ICD-9-CM diagnosis codes occurring within 2 days after anti-TNF-alpha use. Although infusion-related anaphylaxis will occur during or within 1 hour after infusion, a 2-day window was permitted to allow for potential service date discrepancies occurring with claims. With cancer outcomes, including solid cancer, lymphoma, and hematologic malignancies, patients were required to have at least 2 claims with corresponding ICD-9-CM diagnosis codes on 2 distinct service dates. See the Appendix for specific ICD-9-CM diagnosis codes.
Statistical Analysis
An intent-to-treat protocol was followed for data analysis among TNF-naïve users after assigning patients to the IV or SQ groups based on their index medication. Approximately 18.3% in the IV cohort had pharmacy fills for either certolizumab pegol or adalimumab after the index date; 5.8% in the SQ cohort had pharmacy fills for infliximab after the index date. Descriptive 
FIGURE 1
Attrition ) and frequencies were reported for continuous and categorical data, respectively. Propensity score to receive IV versus SQ anti-TNFalpha agents was created via logistic regression with demographics, comorbidities, and health care utilization (Table 1) as independent variables. A 1:1 propensity score matching with maximum acceptable distance of 0.001 was employed to make the groups more comparable. Cox proportional hazard model was used to compare age-sex adjusted incidence rates. Analyses were conducted using SAS version 9.2 (SAS Institute, Inc., Carey, NC). Statistical significance was set at 0.05.
■■ Results Patient Characteristics
After propensity score matching, the IV and SQ cohorts each contained 515 patients with a mean age of 39 years (Table 1) . Median follow-up was 17.5 months in the IV group and 17.7 months in the SQ group. The majority of patients were female (55.7% IV, 52.8% SQ, P = 0.35). At baseline, the most common comorbidity was ulcerative colitis (16.9% IV, 19.0% SQ, P = 0.37).
The most common baseline CD-specific events were obstruction or intestinal stricture (15.5% IV, 16.9% SQ, P = 0.55) and gastrointestinal hemorrhage (14.6% IV, 17.9% SQ, P = 0.15). Few patients had general infection (1.2% IV, 1.7% SQ, P = 0.44); cancer (1.7% IV, 2.1% SQ, P = 0.65); or tuberculosis (0.6% IV, 0% SQ, P = 0.25) at baseline. Health care resource utilization was similar between the IV and SQ cohorts prior to the index visit (Table 1) , suggesting similar overall health status of the 2 treatment groups. The majority of patients in both treatment groups used corticosteroids before beginning an anti-TNF-alpha regimen (62.9% IV, 63.7% SQ, P = 0.80), with approximately half taking aminosalicylates (48.0% IV, 53.0% SQ, P = 0.11).
Effectiveness Measures
Measures of anti-TNF-alpha effectiveness in managing CD showed no between-group differences ( Table 2 ). The combined measure of obstruction, occlusion, stenosis, or intestinal stricture was the most frequently reported CD-specific comorbidity in the IV (139.3 per 1,000 person-years) and SQ (173.0 per 1,000 person-years) groups (P = 0.14). Gastrointestinal hemorrhage (95.7 in IV vs. 109.3 in SQ; P = 0.45); fistula (107.7 in IV vs. 117.7 in SQ; P = 0.64); abscess (115.3 in IV vs. 115.1 in SQ; P = 0.85); and anal fissures (27.4 in IV vs. 17.3% in SQ; P = 0.14) were reported for smaller proportions of patients.
After adjusting for age and gender using the Cox (PH) model, the incidence rates were similar for both groups ( Table 2 ). The incidence rate ratios (IRRs) for the SQ group compared with the IV group were 0.61 (95% confidence interval [CI] = 0.32-1.18, P = 0.14) for anal fissures; 0.97 (95% CI = 0.72- 
Baseline Characteristics for Crohn's Disease Patients Treated with IV Versus SQ Anti-TNF-Alpha Agents
1.30, P = 0.85) for abscess; 1.08 (95% CI = 0.79-1.04, P = 0.64) for fistulae; 1.12 (95% CI = 0.83-1.54, P = 0.45) for gastrointestinal hemorrhage; and 1.22 (95% CI = 0.93-1.59, P = 0.14) for the combined measure of obstruction, occlusion, stenosis, and intestinal stricture.
In addition to the previously mentioned effectiveness measures, the concomitant treatments between the 2 cohorts was also examined. The concomitant treatments among these patients were very similar during the post-index date period (Table 3) , including corticosteroids (64.7% in the IV cohort vs. 61.7% in the SQ cohort, P = 0.33); aminosalicylates (40.4% in the IV cohort vs. 43.7% in the SQ cohort, P = 0.28); immune modifiers (40.0% in the IV cohort vs. 39.6% in the SQ cohort, P = 0.90); antibiotics (43.1% in the IV cohort vs. 46.4% in the SQ cohort, P = 0.29); and surgery (13.8% in the IV cohort vs. 12.0% in the SQ cohort, P = 0.40).
Safety Outcomes
Overall, rates of infection were 114.6 per 1,000 person-years in the IV group and 99.9 in the SQ group (P = 0.24), largely clustered in candidiasis (53.9 in IV group and 34.1 in SQ group, P = 0.08); pneumonia (36.4 in IV group and 45.3 in SQ group, P = 0.34); and sepsis (20.0 in IV group and 22.1 in SQ group, P = 0.98; Table 4 ). Rates of tuberculosis were low for both groups (1.1 per 1,000 person-years in IV group and 3.4 per 1,000 person-year in SQ group, P = 0.35).
For cancer metrics, the median time to event was 16.4 months, and the rate for any type of cancer was similar between the 2 groups (34.0 per 1,000 person-years in IV group, 42.2 in SQ group, P = 0.55), including solid tumors (29.1 per 1,000 person-years in IV group vs. 40.8 in SQ group, P = 0.30); lymphomas (3.3 per 1,000 person-years in IV group vs. 1.1 in SQ group, P = 0.34); and hematologic cancers (1.1 per 1,000 person-years in IV group vs. 0 in SQ group, P value not obtainable; Table 4 ). No between-group difference was seen for the incidence of hepatic-related diseases (40.6 per 1,000 personyears in IV group vs. 50.3 in SQ group, P = 0.41).
After adjusting for age and gender using the Cox (PH) model, the incidence rates for safety metrics were similar for both groups (Table 4 ). The IRRs for the SQ group compared with the IV group were 0.85 (95% CI = 0.62-1.16, P = 0.30) for aggregated infection measure; 1.16 (95% CI = 0.71-1.89, P = 0.55) for all cancers; and 1.23 (95% CI = 0.79-1.92, P = 0.35) for hepatic-related disease.
■■ Discussion
In this real-world analysis of the effectiveness and safety of anti-TNF-alpha agents in the treatment of CD, no statistically significant differences between agents delivered intravenously or subcutaneously were found.
Using CD-specific complications as a measure of effectiveness, no between-group differences were observed in the incidence of anal fissures, gastrointestinal hemorrhage, fistula, abscess, or a combined measure of obstruction, occlusion, stenosis, or intestinal stricture. The efficacy of anti-TNF-alpha agents in inducing and maintaining remission in patients with CD has been demonstrated in numerous clinical trials in comparisons with placebo. [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] The current analysis, however, was unique not only in comparing all 3 anti-TNF-alpha agents approved for the treatment of CD, but also in examining the 
TABLE 3
Concomitant Treatment for CD Patients Treated with IV Versus SQ Anti-TNF-Alpha Agents
little difference between the IV and SQ routes of administration in the incidence of sepsis, tuberculosis, malignancies, hepaticrelated diseases, or most other types of infection.
With little effectiveness and safety differences observed between anti-TNF-alpha agents when used in clinical practice, patient preferences play an important role in the choice of an anti-TNF-alpha agent. The WCOG statement recommends that providers discuss not only the efficacy and safety of anti-TNFalpha agents with their patients, but also the advantages and disadvantages of each delivery method when selecting a treatment for CD. 18 IV treatment may be advantageous for patients who have difficulty complying with a self-injecting regimen or for patients who will feel a sense of safety when medical personnel are present. SQ administration may be advantageous for patients who desire flexibility and convenience because the medication can be administered at a time selected by the patient. Self-administration may also be preferred by patients who are active or in the workforce, since it eliminates the need to travel to a medical facility. 34 Such a collaboration between the patient and provider is also supported by a recent survey of patients with CD, which evaluated their preferences for anti-TNF-alpha treatment delivery. 34 In that survey, patients rated communication with their physicians as highly important when choosing CD treatment, and they indicated they were interested in learning about treatment options. However, fewer effects between IV and SQ agents. Furthermore, the effectiveness measures used in the current study differed from previous clinical trials and other studies of CD therapies. Whereas previous studies used aggregate efficacy measures of complete or partial clinical response, each CD-specific complication was assessed separately. The claims analysis presented here also provides updated data on the use of anti-TNF-alpha agents in usual practice settings, filling gaps left by earlier research. For example, where a previous study noted the need for further research on the efficacy of the 2 SQ anti-TNF-alpha agents (adalimumab and certolizumab) in reducing the incidence of fistulizing CD, our analysis found no difference between these 2 SQ agents and the IV infliximab in occurrence of fistulae. 27 These results indicate that in clinical practice, IV and SQ anti-TNF-alpha agents are similarly effective in controlling CD-specific comorbidities.
The safety outcomes assessed in this analysis were also similar for IV and SQ anti-TNF-alpha agents. Safety concerns associated with anti-TNF-alpha agents have been documented in the literature and include serious and opportunistic infections, tuberculosis, and hematologic malignancies. [22] [23] [24] [25] However, randomized clinical trials found rates of serious adverse events to be similar between biologic agents and placebo, and a study of adalimumab in clinical practice found rates of adverse events consistent with clinical trials. 22, [28] [29] [30] [31] [32] [33] The results of this real-world analysis found 
TABLE 4
Safety Outcomes Associated with IV Versus SQ Anti-TNF-Alpha Agents Among CD Patients than half of the patients reported discussing anti-TNF-alpha treatment alternatives with their physicians. 35 Given the lack of observed differences in effectiveness and safety, patient preferences should be considered when selecting an anti-TNF-alpha agent for the treatment of CD, and patients should be educated regarding all available treatment options to make informed decisions with their physicians.
Limitations
There are several limitations that must be acknowledged. First, the outcome measures used in this study were obtained from ICD-9-CM codes on administrative claims. The diagnostic codes may have been entered incorrectly, miscoding may have occurred, or outcomes of interest may not have been captured. Second, as mentioned, the average follow-up was 17.5 months in the IV group and 17.7 months in the SQ group. While anti-TNFalpha clinical trials reporting the occurrence of malignancies typically had median follow-up periods of 1 to 2 years, these studies also acknowledged that the follow-up times were relatively short for agents that are taken over the long term. [22] [23] [24] Some outcome measures, such as cancer, might take a longer time to develop and merit further research. Third, given that this study followed an "intent to treat" study design, treatment adherence was not measured; thus, it was not clear if patients switched to other CD therapy after initiation of the index anti-TNF-alpha treatment. Finally, demographic and clinical baseline differences were observed between cohorts. A propensity score matching approach was adopted to create balanced cohorts; however, unobserved baseline difference might have remained.
■■ Conclusions
The findings from this study suggest that after adjusting for baseline characteristics, effectiveness and safety outcomes appear to be comparable between IV and SQ anti-TNF-alpha agents in patients with CD. With similar outcomes, other considerations, such as convenience of administration and patient preference, might play a more prominent role in choice of agent. Health care providers and health payers should inform patients with CD about the range of options available when selecting an anti-TNF-alpha agent.
ICD-9-CM Diagnosis Codes Effectiveness metrics
Abscess 5672x, 99859, 0400x, 566xx, 6822x, 5695x, 6825x, 5401x, 56961, 5695x, 5672x, 6829x, 5672x, 99859, 5672x, 5650x Anal fissure 5650x Fistula 5651x, 5374x, 56981, 566xx, 9986x, 6191x, 5374x Gastrointestinal hemorrhage 5693x, 5789x, 5781x, 5789x, 7921x Obstruction/occlusion/stenosis/stricture of intestine 56081, 5373x, 5601x, 56089, 5601x, 5609x, 5692x, 5373x 
APPEnDIx
ICD-9-CM Codes for Effectiveness and Safety Metrics
